The activity of closantel as an equine antiparasitic agent.
Eighteen pony foals were experimentally infected with 500 third stage larvae of Strongylus vulgaris at 2 weeks, and at 2, 4, 6 and 8 months after birth. For the duration of the study, all foals were kept in the same pasture with their mothers to allow natural infection with other parasites by exposure to a contaminated environment. Twelve of the foals were utilized in groups of 3 and treated orally five times at two month intervals starting at one month of age with closantel at doses of 5, 10, 20 or 40 mg kg-1. Ten months after birth the foals were necropsied to determine the parasitic burdens in the gastrointestinal tracts and the cranial mesenteric arteries. The results indicate a high antiparasitic activity of closantel against larval stages of Gasterophilus intestinalis and S. vulgaris, as well as against adult S. vulgaris, S. edentatus, Anoplocephala perfoliata and Triodontophorus spp., when used at doses of 20 or 40 mg kg-1.
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D002590:Cestode Infections / Q000662:veterinary; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses / Q000469:parasitology; D009198:Myiasis / Q000662:veterinary; D010272:Parasitic Diseases / Q000188:drug therapy; D010273:Parasitic Diseases, Animal; D012457:Salicylamides / Q000627:therapeutic use*; D012458:Salicylanilides / Q000627:therapeutic use*; D013319:Strongyle Infections, Equine / Q000188:drug therapy*
D000871:Anthelmintics; D012457:Salicylamides; D012458:Salicylanilides; C023342:closantel